ALLO-HSCT FOLLOWING RIC FOR ELDERLY PATIENTS (60 YEARS AND OLDER) WITH HEMATOLOGICAL MALIGNANCIES USING UNRELATED DONORS: A RETROSPECTIVE STUDY OF THE SFGM-TC.
(Abstract release date: 05/21/15)
EHA Library. El Cheikh J. 06/12/15; 103149; S130
Disclosure(s): INSTITUT PAOLI CALMETTEStransplantation
Dr. Jean El Cheikh
Contributions
Contributions
Abstract
Abstract: S130
Type: Oral Presentation
Presentation during EHA20: From 12.06.2015 12:30 to 12.06.2015 12:45
Location: Room Lehar 1 + 2
Background
The use of unrelated donors (URD) in patients aged of 60 years or more has drastically increased in the past few years. To date, there are only limited data on URD allo-HSCT in elderly patients (60 years or more).
Aims
The purpose of the current study is to describe outcomes in a large cohort of patients aged 60 years or older, who received a RIC URD allo-HSCT in recent years.
Methods
Between 2008 and 2012, 516 consecutive patients aged of 60 years or more, who received a first allo-HSCT for hematological malignancies from an URD after a RIC regimen in France were included. Conditioning regimen was fludarabine-based in 91% of the patients. Two groups of patients were defined: patients with age at allo-HSCT less than 65 years old ('URD<65 group', n=374) and patients who were aged of 65 years old or more ('URD ≥ 65 group', n=142).
Results
Patient characteristics were similar between the 2 groups. The median follow-up was 36 months (range, 0.36-73.5) for URD<65 group and 32 months (range, 0.03-72) for URD≥65 group. During evolution, the cumulative incidence (CI) of grade II–IV acute GvHD was 32% in URD<65 group and 32% in URD≥65 group (p= 0.975) while the CI of chronic GvHD at 2 years was 25 % and 26%, respectively (p= 0.701). CI of non-relapse mortality (NRM), disease free survival (DFS) and overall survival (OS) were not different between the 2 groups Multivariate analysis for NRM, DFS and OS show that age by itself has no influence on outcomes
Summary
These data suggest equivalence of outcome between URD<65 group and URD≥65 group after RIC URD allo-HSCT. Age by itself thus appears not to be a limitation in this particular population of elderly patients.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Elderly, Unrelated donor
Session topic: Stem cell transplantation: Clinical 1
Type: Oral Presentation
Presentation during EHA20: From 12.06.2015 12:30 to 12.06.2015 12:45
Location: Room Lehar 1 + 2
Background
The use of unrelated donors (URD) in patients aged of 60 years or more has drastically increased in the past few years. To date, there are only limited data on URD allo-HSCT in elderly patients (60 years or more).
Aims
The purpose of the current study is to describe outcomes in a large cohort of patients aged 60 years or older, who received a RIC URD allo-HSCT in recent years.
Methods
Between 2008 and 2012, 516 consecutive patients aged of 60 years or more, who received a first allo-HSCT for hematological malignancies from an URD after a RIC regimen in France were included. Conditioning regimen was fludarabine-based in 91% of the patients. Two groups of patients were defined: patients with age at allo-HSCT less than 65 years old ('URD<65 group', n=374) and patients who were aged of 65 years old or more ('URD ≥ 65 group', n=142).
Results
Patient characteristics were similar between the 2 groups. The median follow-up was 36 months (range, 0.36-73.5) for URD<65 group and 32 months (range, 0.03-72) for URD≥65 group. During evolution, the cumulative incidence (CI) of grade II–IV acute GvHD was 32% in URD<65 group and 32% in URD≥65 group (p= 0.975) while the CI of chronic GvHD at 2 years was 25 % and 26%, respectively (p= 0.701). CI of non-relapse mortality (NRM), disease free survival (DFS) and overall survival (OS) were not different between the 2 groups Multivariate analysis for NRM, DFS and OS show that age by itself has no influence on outcomes
Summary
These data suggest equivalence of outcome between URD<65 group and URD≥65 group after RIC URD allo-HSCT. Age by itself thus appears not to be a limitation in this particular population of elderly patients.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Elderly, Unrelated donor
Session topic: Stem cell transplantation: Clinical 1
Abstract: S130
Type: Oral Presentation
Presentation during EHA20: From 12.06.2015 12:30 to 12.06.2015 12:45
Location: Room Lehar 1 + 2
Background
The use of unrelated donors (URD) in patients aged of 60 years or more has drastically increased in the past few years. To date, there are only limited data on URD allo-HSCT in elderly patients (60 years or more).
Aims
The purpose of the current study is to describe outcomes in a large cohort of patients aged 60 years or older, who received a RIC URD allo-HSCT in recent years.
Methods
Between 2008 and 2012, 516 consecutive patients aged of 60 years or more, who received a first allo-HSCT for hematological malignancies from an URD after a RIC regimen in France were included. Conditioning regimen was fludarabine-based in 91% of the patients. Two groups of patients were defined: patients with age at allo-HSCT less than 65 years old ('URD<65 group', n=374) and patients who were aged of 65 years old or more ('URD ≥ 65 group', n=142).
Results
Patient characteristics were similar between the 2 groups. The median follow-up was 36 months (range, 0.36-73.5) for URD<65 group and 32 months (range, 0.03-72) for URD≥65 group. During evolution, the cumulative incidence (CI) of grade II–IV acute GvHD was 32% in URD<65 group and 32% in URD≥65 group (p= 0.975) while the CI of chronic GvHD at 2 years was 25 % and 26%, respectively (p= 0.701). CI of non-relapse mortality (NRM), disease free survival (DFS) and overall survival (OS) were not different between the 2 groups Multivariate analysis for NRM, DFS and OS show that age by itself has no influence on outcomes
Summary
These data suggest equivalence of outcome between URD<65 group and URD≥65 group after RIC URD allo-HSCT. Age by itself thus appears not to be a limitation in this particular population of elderly patients.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Elderly, Unrelated donor
Session topic: Stem cell transplantation: Clinical 1
Type: Oral Presentation
Presentation during EHA20: From 12.06.2015 12:30 to 12.06.2015 12:45
Location: Room Lehar 1 + 2
Background
The use of unrelated donors (URD) in patients aged of 60 years or more has drastically increased in the past few years. To date, there are only limited data on URD allo-HSCT in elderly patients (60 years or more).
Aims
The purpose of the current study is to describe outcomes in a large cohort of patients aged 60 years or older, who received a RIC URD allo-HSCT in recent years.
Methods
Between 2008 and 2012, 516 consecutive patients aged of 60 years or more, who received a first allo-HSCT for hematological malignancies from an URD after a RIC regimen in France were included. Conditioning regimen was fludarabine-based in 91% of the patients. Two groups of patients were defined: patients with age at allo-HSCT less than 65 years old ('URD<65 group', n=374) and patients who were aged of 65 years old or more ('URD ≥ 65 group', n=142).
Results
Patient characteristics were similar between the 2 groups. The median follow-up was 36 months (range, 0.36-73.5) for URD<65 group and 32 months (range, 0.03-72) for URD≥65 group. During evolution, the cumulative incidence (CI) of grade II–IV acute GvHD was 32% in URD<65 group and 32% in URD≥65 group (p= 0.975) while the CI of chronic GvHD at 2 years was 25 % and 26%, respectively (p= 0.701). CI of non-relapse mortality (NRM), disease free survival (DFS) and overall survival (OS) were not different between the 2 groups Multivariate analysis for NRM, DFS and OS show that age by itself has no influence on outcomes
Summary
These data suggest equivalence of outcome between URD<65 group and URD≥65 group after RIC URD allo-HSCT. Age by itself thus appears not to be a limitation in this particular population of elderly patients.
Keyword(s): Allogeneic hematopoietic stem cell transplant, Elderly, Unrelated donor
Session topic: Stem cell transplantation: Clinical 1
{{ help_message }}
{{filter}}